Boehringer Ingelheim v. Sun Pharmaceutical: TRIJARDY XR Consent Judgment After 1,710 Days
Boehringer Ingelheim and its affiliates secured a consent judgment against Sun Pharmaceutical and Ohm Laboratories protecting TRIJARDY XR — a triple-combination diabetes tablet — across 11 asserted patents. The case ran for 1,710 days before resolving without a merits trial, with Sun enjoined from launching its generic ANDA products until all patent terms expire.
An 11-patent ANDA blockade: how Boehringer locked out Sun’s TRIJARDY XR generics
Filed in November 2020 in the District of Delaware before Judge Colm F. Connolly, this ANDA infringement action is one of several consolidated cases in which Boehringer Ingelheim Corporation and Boehringer Ingelheim International GmbH (collectively Boehringer) asserted a portfolio of eleven patents against Sun Pharmaceutical Industries, Inc. and Ohm Laboratories, Inc. The patents cover the branded product TRIJARDY XR — a once-daily extended-release tablet combining empagliflozin, linagliptin, and metformin hydrochloride for type 2 diabetes management, available in four dosage strengths.
The case closed on 30 July 2025 via a consent judgment — a negotiated court order that carries the force of a binding injunction without a full merits trial. The consent judgment declares all eleven patents (the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents) valid, enforceable, and infringed by Sun’s ANDA products. Sun is permanently enjoined from making, using, selling, or importing the generic ANDA products in the United States until each patent’s expiry, including any extensions or pediatric exclusivity. Importantly, the order preserves Sun’s right to challenge those same patents in relation to a different product not covered by the identified ANDAs.
The 1,710-day duration, spanning multiple consolidated actions across at least three separate case numbers, suggests protracted negotiation rather than imminent trial defeat — consent judgments in ANDA matters typically reflect a commercial settlement in which the generic party accepts a delayed market entry in exchange for certainty. The public record is silent on any agreed entry date or licensing arrangement, which is common when parties reach confidential co-settlement terms alongside the consent judgment. The no-costs provision is consistent with a negotiated resolution rather than a contested adjudication.
Filing to Consent Judgment in 1710 days
1,710 days — nearly 4.7 years, consistent with complex multi-patent ANDA litigation in D. Del.
Consent judgment decoded: what Sun’s injunction means for both parties
Consent judgment: an injunction by agreement, not after trial
A consent judgment is a court-entered order reflecting the parties’ negotiated agreement. Unlike a trial verdict, it does not require the court to find facts independently — but once entered, it carries full injunctive force. Here, all eleven patents are declared valid and infringed by stipulation, and the court retains jurisdiction to enforce compliance. Sun retains only the narrow right to challenge those patents for non-ANDA products.
Binding injunction — no merits trial requiredBoehringer secures full portfolio protection through patent expiry
Boehringer obtained the strongest available ANDA outcome short of a trial win: a court order that formally validates all eleven patents and blocks Sun’s generic entry across all four TRIJARDY XR dosage strengths. The order explicitly captures any future patent term extensions, adjustments, and pediatric exclusivity — and reserves Boehringer’s right to seek further modifications if additional regulatory exclusivities arise. TRIJARDY XR’s commercial runway is legally secured.
Full exclusivity preservedSun accepts injunction but retains challenge rights for future products
Sun and Ohm Laboratories are enjoined from commercialising the specific ANDA products, but the consent judgment explicitly carves out Sun’s right to challenge the eleven patents in connection with any product beyond those identified ANDAs. This preservation clause is commercially significant: it suggests Sun may pursue a reformulated or distinct product pathway without the estoppel risk that a full trial loss would have created.
Future challenge rights preservedMulti-combination diabetes tablet IP: a high-stakes exclusivity model
TRIJARDY XR represents the growing trend of SGLT2-inhibitor combination therapies, where patent portfolios are layered across the active ingredients, formulation, and dosage regimen. Eleven patents across one product signals a defensive stacking strategy that substantially raises the cost and complexity of generic ANDA challenges. For competitors in the empagliflozin or linagliptin space, this outcome reinforces the durability of combination-product patent portfolios when litigated in Delaware.
Patent stacking — delayed generic entryFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Pharmaceutical innovator — holder of US7579449B2 and 10 further TRIJARDY XR patentsSearch in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Generic pharmaceutical manufacturer; filed ANDAs seeking to launch empagliflozin/linagliptin/metformin ER tabletsSearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Ohm Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | Bryce A. Cooper | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Charles B. Klein | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s operative language — declaring all eleven patents ‘valid, enforceable, and infringed’ — creates a court-entered record that carries full preclusive effect against Sun’s ANDA products. The carve-out language (‘nothing precludes Sun from challenging… in connection with a product other than a product described in ANDA Nos. 212343, 212339, 214843, 215873, and 215529’) was deliberately drafted to limit Sun’s estoppel exposure, suggesting the parties negotiated the scope of preclusion as a material term. The no-costs provision and dismissal without prejudice of all remaining claims are characteristic of a commercially negotiated resolution.
US7579449B2 — empagliflozin/linagliptin/metformin combination therapy
US7579449B2 is one of eleven patents asserted by Boehringer Ingelheim in this ANDA litigation, all covering aspects of TRIJARDY XR — an extended-release oral tablet combining empagliflozin (an SGLT2 inhibitor), linagliptin (a DPP-4 inhibitor), and metformin hydrochloride (a biguanide). The combination addresses type 2 diabetes through three complementary mechanisms of action. Extended-release formulation patents in this class typically cover the dosage form, release profile, and specific weight ratios of active ingredients — each layer adding independent validity and enforceability.
From a competitive intelligence standpoint, the eleven-patent assertion against a single product signals that Boehringer has constructed a defensive patent thicket around TRIJARDY XR that mirrors its approach to other SGLT2-combination assets, including JARDIANCE and GLYXAMBI. Any company developing a fixed-dose combination incorporating empagliflozin or linagliptin — whether as a two-drug or three-drug regimen — should treat this portfolio as a primary FTO target. The consent judgment’s outcome strengthens the presumption of validity across all eleven patents and raises the evidentiary bar for any future challenger.
Should you run an FTO against US7579449B2 and the TRIJARDY XR patent portfolio?
Any pharmaceutical or biotech company developing a fixed-dose combination tablet containing an SGLT2 inhibitor, a DPP-4 inhibitor, or metformin in extended-release form should treat this patent family as a priority FTO target. The consent judgment — which formally upholds all eleven patents as valid and enforceable — substantially strengthens their litigation posture. Generic manufacturers, authorised generic partners, and 505(b)(2) applicants developing competing diabetes combination products face elevated injunction risk if any of these claims read on their formulations.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their candidate formulations against the full Boehringer empagliflozin/linagliptin/metformin portfolio — including claim-level analysis, expiry timelines, and patent term extension status. By ingesting your formulation parameters, Eureka can flag claim overlap, identify design-around white space, and benchmark your risk profile against comparable ANDA outcomes in Delaware. Start your FTO analysis before IND filing to avoid costly late-stage reformulation.
Run a freedom-to-operate analysis on US7579449B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: SGLT2-inhibitor combination therapy litigation in D. Del.
Cases involving multi-patent ANDA assertions over SGLT2-inhibitor and DPP-4-inhibitor combination therapies in the Delaware District Court, including consent judgment outcomes.
Related patent case — similar technology
Comparable case in the same technology domain. Patent holder and defendant reached resolution after proceedings.
SettledRelated infringement action — same court
Comparable Sun’s 5 mg/2.5 mg/1000 mg, 10 mg/5 mg/1000 mg, 12.5 mg/2.5 mg/1000 mg, and 25 mg/5 mg/1000 mg empagliflozinlinagliptin-metformin hydrochloride extended-release tablets-adjacent infringement action. Patent enforcement dynamics analysed in depth.
Active · District CourtRelated invalidity challenge — appellate outcome
Combined invalidity and infringement action in the same technology space. Decided after substantive proceedings.
DecidedBoehringer-Ingelheim’s broader IP enforcement history
Boehringer-Ingelheim’s full litigation history covering prior enforcement, licensing activity, and inter partes review proceedings.
Portfolio viewWhat this case signals for the SGLT2-inhibitor combination therapy IP landscape
Boehringer’s consent judgment outcome illustrates the commercial leverage that multi-patent ANDA portfolios generate against generic entrants in complex combination drug litigation.
Patent stacking in combination therapies raises the generic challenge bar significantly
Asserting eleven patents across a single combination product means a generic entrant must successfully invalidate or design around the entire portfolio — not just one claim. This case illustrates how innovators use layered IP coverage across active ingredients, formulation, and method-of-use claims to create near-impenetrable ANDA barriers in district court.
Consent judgments in ANDA cases often signal negotiated entry dates — watch for side agreements
When an ANDA case resolves via consent judgment with no costs awarded and a dismissal without prejudice, a confidential settlement authorising a future generic entry date is a common commercial structure. The public record here is silent on any such arrangement, but stakeholders monitoring the TRIJARDY XR generic market should track Sun’s ANDA status with FDA for any authorised generic signals.
Sun’s preserved challenge rights create a residual litigation risk for Boehringer
The explicit carve-out allowing Sun to challenge the eleven patents for non-ANDA products is not boilerplate — it suggests Sun may pursue a reformulation, a combination with a different third agent, or a new dosage form. IP teams monitoring empagliflozin and linagliptin freedom-to-operate should model this scenario in their landscape analysis.
Delaware’s consolidated ANDA docket structure amplifies settlement pressure on generics
The consolidation of at least seven separate case numbers into three master actions under Judge Connolly, combined with Delaware’s procedural rigour, concentrated litigation costs and discovery burden on Sun. This structural pressure — rather than any single patent weakness — is likely what drove the consent judgment. Generic entrants should factor D. Del. consolidation risk into early ANDA challenge cost models.
Boehringer-Ingelheim v Sun — key questions answered
The consent judgment, entered 30 July 2025, declared all eleven asserted patents valid, enforceable, and infringed by Sun’s ANDA products. Sun and Ohm Laboratories are permanently enjoined from making, selling, or importing the generic TRIJARDY XR tablets in the US until all patent terms expire, including any extensions or pediatric exclusivity.
Boehringer asserted eleven patents, identified in the consent judgment as the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents, collectively covering the empagliflozin/linagliptin/metformin extended-release combination product TRIJARDY XR. US7579449B2 is among the identified asserted patents.
Yes, in limited circumstances. The consent judgment expressly preserves Sun’s right to challenge the eleven patents in connection with any product other than those described in the five identified ANDA numbers. This carve-out prevents full estoppel and may allow Sun to contest the patents if it develops a distinct product formulation in the future.
In this context, the remaining complaints and claims across the consolidated actions are dismissed without prejudice as part of the negotiated consent judgment. This means no party is precluded from relitigating claims that were not adjudicated on the merits — though the injunction and patent validity declarations in the consent judgment itself are binding. No costs or attorneys’ fees were awarded to either party.
ANDA litigation commonly involves multiple case filings as new patents are listed in the Orange Book or as additional ANDA submissions trigger 30-month stays. The consolidation of at least seven civil action numbers into three master actions before Judge Connolly in Delaware suggests Boehringer pursued a rolling enforcement strategy as Sun filed successive ANDAs covering different dosage strengths or formulation variations of the combination product.
Monitor TRIJARDY XR generic risk and SGLT2-combination FTO in one platform
PatSnap Eureka tracks all eleven TRIJARDY XR patents — including expiry, term extensions, and new ANDA activity — in real time. Run a freedom-to-operate analysis against your diabetes combination pipeline before the next filing deadline.
PatSnap Eureka searches patents and litigation data to answer instantly.